Cue Biopharma, Inc. (CUE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Cue Biopharma, Inc. reported revenue of $27.47M, up 195.7% from the prior year. The company ran a net loss, with a net margin of -96.9%. It held $42.21M in total assets against $15.78M in total liabilities.
Key ratios (FY2025)
-96.7%
Operating margin
-96.9%
Net margin
-100.6%
Return on equity
+195.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M | $3.15M | $3.46M | $1.14M | — | — |
| Operating Income | -$26.55M | -$41.50M | -$52.15M | -$53.23M | -$43.71M | -$45.04M | -$36.77M | -$38.70M | -$23.23M | — |
| Net Income | -$26.60M | -$40.67M | -$50.73M | -$53.01M | -$44.16M | -$44.78M | -$36.70M | -$38.98M | -$23.23M | — |
| EPS (Diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | — | — | — | — | — |
| Total Assets | $42.21M | $32.19M | $61.53M | $91.28M | $83.40M | $99.53M | $71.61M | $45.36M | $66.95M | — |
| Total Liabilities | $15.78M | $14.69M | $24.45M | $25.60M | $17.91M | $20.62M | $17.02M | $11.39M | $5.35M | — |
| Shareholders' Equity | $26.43M | $17.50M | $37.09M | $65.68M | $65.49M | $78.91M | $54.58M | $33.97M | $61.61M | $15.17M |
| Cash & Equivalents | $27.14M | $22.46M | $48.51M | $51.61M | $64.37M | $74.87M | $44.29M | $20.80M | — | — |
| Operating Cash Flow | -$21.69M | -$36.33M | -$39.96M | -$41.81M | -$38.84M | -$32.49M | -$30.80M | -$26.41M | -$12.14M | — |
| Capital Expenditures | $177.0K | $66.0K | $0 | $171.0K | $913.0K | $595.3K | $46.4K | $1.85M | $1.03M | — |
| Shares Outstanding | 96.62M | 61.82M | 47.22M | 47.22M | 32.20M | 30.35M | 26.56M | 20.70M | 19.46M | — |